ESTRADURIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ESTRADURIN (ESTRADURIN).
Estrogen receptor agonist; estradiol valerate is a prodrug that releases estradiol, which binds to and activates estrogen receptors (ERα and ERβ), modulating gene transcription and cellular signaling.
| Metabolism | Hepatic via CYP3A4; estradiol primarily metabolized to estrone and estriol, conjugated to sulfates and glucuronides. |
| Excretion | Renal: 50-80% as glucuronide and sulfate conjugates, biliary/fecal: 20-30% as conjugates |
| Half-life | Terminal half-life: 5-7 days (estradiol valerate); prolonged due to esterification and slow release from adipose tissue. Clinical context: steady-state achieved after 2-3 months with monthly dosing. |
| Protein binding | 97-99% bound to albumin and sex hormone-binding globulin (SHBG). |
| Volume of Distribution | Vd: 20-30 L/kg; extensive distribution into adipose tissue and other estrogen-responsive tissues. |
| Bioavailability | Intramuscular: 100% (complete absorption); oral: not applicable (prodrug; estradiol valerate is rapidly hydrolyzed to estradiol). |
| Onset of Action | Intramuscular: 2-5 hours for measurable serum estradiol levels; clinical effects (e.g., hot flush reduction) within 1-2 weeks. |
| Duration of Action | Intramuscular: 3-4 weeks per injection; clinical effects last for the dosing interval. Note: prolonged duration due to depot effect. |
Estradurin (polyestradiol phosphate) is administered intramuscularly at a dose of 40 mg every 2 to 4 weeks for the treatment of prostate cancer.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment guidelines are available for renal impairment. Caution is advised in patients with severe renal dysfunction. |
| Liver impairment | No specific dose adjustment guidelines are available for hepatic impairment. Caution is advised in patients with severe hepatic disease. |
| Pediatric use | Not indicated for use in pediatric patients. No established dosing guidelines. |
| Geriatric use | Elderly patients may be more sensitive to estrogenic effects; use lower initial doses and titrate based on response and tolerability. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ESTRADURIN (ESTRADURIN).
| Breastfeeding | Estrogen is excreted into breast milk. The M/P ratio is not well defined. Estrogens may reduce milk quality and quantity. Avoid use during breastfeeding due to potential adverse effects on the infant. |
| Teratogenic Risk | First trimester: Estrogen exposure is associated with a risk of congenital anomalies including cardiac defects and vaginal adenosis. Second and third trimesters: Continued exposure may increase risk of fetal genital tract abnormalities, low birth weight, and potential long-term reproductive tract changes. |
■ FDA Black Box Warning
Estrogens should not be used to prevent cardiovascular disease or dementia. Increased risk of endometrial cancer in women with intact uterus; unopposed estrogens may increase risk of stroke and DVT.
| Serious Effects |
Breast cancer (known/suspected), estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, active DVT/PE/thromboembolic disorders, history of thrombophlebitis, pregnancy, liver disease or impairment.
| Precautions | Risk of endometrial hyperplasia/cancer, thromboembolic disorders, cardiovascular disorders, breast cancer, dementia, gallbladder disease, hypercalcemia, visual abnormalities, fluid retention. |
Loading safety data…
| Fetal Monitoring |
| Monitor fetal growth and development via ultrasound; assess for congenital anomalies; monitor maternal blood pressure and signs of thromboembolism. |
| Fertility Effects | May impair fertility due to suppression of gonadotropin secretion, leading to anovulation; effects are reversible upon discontinuation. |